Disease · MONDO_0006031
chronic rhinosinusitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic rhinosinusitis. Diseases, record MONDO_0006031. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006031
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs60
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MEPOLIZUMAB | CHEMBL2108429 | Antibody | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 2 | Drugs and targets |
| MOMETASONE FUROATE | CHEMBL1161 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| BETAMETHASONE DIPROPIONATE | CHEMBL1200384 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 2 | Drugs and targets |
| FLUTICASONE PROPIONATE | CHEMBL1473 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| POVIDONE-IODINE | CHEMBL1201724 | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets | |
| TRIAMCINOLONE | CHEMBL1451 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 2 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
1 to 10 of 60
See all 60 drugsTargets82
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 15 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 3 | Voltage-gated L-type calcium channel blocker | Early phase 1 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 3 | Voltage-gated L-type calcium channel blocker | Early phase 1 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 3 | Voltage-gated L-type calcium channel blocker | Early phase 1 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 3 | Voltage-gated L-type calcium channel blocker | Early phase 1 | https://conductscience.org/library/genes/779 | Drugs and targets |
| CFTR | Cystic fibrosis transmembrane conductance regulator | 3 | Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator | Early phase 1 | https://conductscience.org/library/genes/1080 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 2 | Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist | Phase 2 | https://conductscience.org/library/genes/153 | Drugs and targets |
| IL5 | Interleukin-5 | 2 | Interleukin-5 inhibitor | Approval | https://conductscience.org/library/genes/3567 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 1/2 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/148 | Drugs and targets |
1 to 10 of 82
See all 82 targetsTrials71
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01623323 | Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps | Phase 3 | 705 | 2016-03-01 | Chronic Sinusitis With or Without Nasal Polyps | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
| NCT05248997 | Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis | Phase 3 | 261 | 2025-03-26 | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | RIMEGEPANT | Its record names the disease | ClinicalTrials.gov |
| NCT01623310 | 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device | Phase 3 | 223 | 2018-01-24 | Nasal Polyps | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
| NCT05219968 | Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults | Phase 3 | 196 | 2025-05-02 | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | MOMETASONE FUROATE | Its record names the disease | ClinicalTrials.gov |
| NCT02182492 | Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis After Endoscopic Sinus Surgery | Not applicable | 187 | 2018-09-25 | Chronic Rhinosinusitis, Endoscopic Sinus Surgery | CLARITHROMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT05295459 | Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) | Phase 3 | 182 | 2026-02-19 | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | MOMETASONE FUROATE | Its record names the disease | ClinicalTrials.gov |
| NCT01608308 | Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery | Not applicable | 62 | 2015-09-04 | Chronic Sinusitis | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov |
| NCT00924404 | Xylitol Versus Saline in Chronic Sinusitis | Not applicable | 53 | 2017-08-09 | Chronic Sinusitis | XYLITOL | Its record names the disease | ClinicalTrials.gov |
| NCT00465530 | Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children | Not applicable | 40 | 2013-05-29 | Sinusitis | GENTAMICIN, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01700725 | Gulf War Illness Nasal Irrigation Study | Phase 2 | 40 | 2019-05-21 | Persian Gulf Syndrome, Chronic Sinusitis, Fatigue, Acute Sinusitis | XYLITOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 71
See all 71 trialsComparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rimegepant vs Placebo: deaths from any cause | 0 of 99 | 0 of 105 | 204 | NCT05248997 | Trial comparisons |
| Rimegepant vs Placebo: serious adverse events | 0 of 99 | 0 of 105 | 204 | NCT05248997 | Trial comparisons |
| LYR-210 vs Sham Procedure Control: Participants With Rescue Treatments for CRS Through Week 24 | 12 of 124 | 7 of 66 | 190 | NCT05219968 | Trial comparisons |
| Glucocorticoid vs Clarithromycin: serious adverse events | 0 of 93 | 0 of 94 | 187 | NCT02182492 | Trial comparisons |
| LYR-210 vs Sham Procedure Control: Rescue Treatment Requirement Through Week 24 | 12 of 111 | 7 of 61 | 172 | NCT05295459 | Trial comparisons |
| LYR-210 vs Sham Procedure Control: deaths from any cause | 0 of 112 | 0 of 60 | 172 | NCT05295459 | Trial comparisons |
| LYR-210 vs Sham Procedure Control: serious adverse events | 2 of 112 | 0 of 60 | 172 | NCT05295459 | Trial comparisons |
| IV Acetaminophen vs Control: Number of Participants Who Received Intraoperative Supplemental Fentanyl | 9 of 31 | 4 of 29 | 60 | NCT01608308 | Trial comparisons |
| IV Acetaminophen vs Control: Number of Participants Who Experienced Postoperative Morbidity (Nausea) | 13 of 31 | 10 of 29 | 60 | NCT01608308 | Trial comparisons |
| IV Acetaminophen vs Control: serious adverse events | 0 of 31 | 0 of 29 | 60 | NCT01608308 | Trial comparisons |
1 to 10 of 25
See all 25 comparisons in its trialsPapers from its trials62
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006031
GET https://conductscience.org/api/diseases/v1/MONDO_0006031/drugs?page=2